Background-In the Third International Study on Syncope of Uncertain Etiology (ISSUE-3), cardiac pacing was effective in reducing recurrence of syncope in patients with presumed neurally mediated syncope (NMS) and documented asystole but syncope still recurred in 25% of them at 2 years. We have investigated the role of tilt testing (TT) in predicting recurrences. Methods and Results-In 136 patients enrolled in the ISSUE-3, TT was positive in 76 and negative in 60. An asystolic response predicted a similar asystolic form during implantable loop recorder monitoring, with a positive predictive value of 86%. The corresponding values were 48% in patients with non-asystolic TT and 58% in patients with negative TT (P=0.001 versus asystolic TT). Fifty-two patients (26 TT+ and 26 TT-) with asystolic neurally mediated syncope received a pacemaker. Syncope recurred in 8 TT+ and in 1 TT-patients. At 21 months, the estimated product-limit syncope recurrence rates were 55% and 5%, respectively (P=0.004). The TT+ recurrence rate was similar to that seen in 45 untreated patients (control group), which was 64% (P=0.75). The recurrence rate was similar between 14 patients with asystolic and 12 with non-asystolic responses during TT (P=0.53). Conclusions-Cardiac pacing was effective in neurally mediated syncope patients with documented asystolic episodes in whom TT was negative; conversely, there was insufficient evidence of efficacy from this data set in patients with a positive TT even when spontaneous asystole was documented. Present observations are unexpected and need to be confirmed by other studies. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01463358.
T he randomized, double-blind, Third International Study on Syncope of Uncertain Etiology (ISSUE-3) showed that dual-chamber permanent pacing was effective in reducing the recurrence of syncope in patients ≥40 years with severe asystolic neurally mediated syncope (NMS) documented by implantable loop recorder (ILR). 1 Nevertheless, patients who had received pacing therapy had an estimated syncopal recurrence rate of 25% at 2 years. Previous randomized controlled trials 2-6 enrolled patients with a positive tilt testing (TT). In ISSUE-3, only about half of the patients had a positive test. Because of its sequential design, the study lacked the power to make any subgroup analysis. The aim of this study was to investigate the role of TT response in predicting syncopal recurrence in the whole ISSUE-3 population.
Methods

Patient Selection
The multicenter, prospective ISSUE-3 study included patients ≥40 years who had experienced ≥3 syncopal episodes with a clinically assessed neurally mediated mechanism (presumed) in the previous 2 years. NMS was defined as reflex syncope, with the exception of carotid sinus syndrome, with a sufficiently severe clinical presentation to warrant specific treatment. These individuals received an ILR and were followed up. In accordance with the guidelines of the European Society of Cardiology, 7 NMS was diagnosed when the clinical history was consistent with NMS and competing diagnoses had been excluded. Detailed inclusion criteria and study protocol have been published previously. 1, 8 TT was recommended, but its result was not taken into account in the subsequent management. The Italian protocol 9 was recommended, which consists of 60° to 70º passive tilting for 20 minutes or until syncope occurs. If the passive tilt phase did not induce syncope, 0.4mg sublingual nitroglycerine spray was administered to the patient while the table was maintained in the same position; the test was continued for 15 minutes after pharmacological challenge. TT was considered positive if syncope occurred in the presence of hypotension with or without bradycardia; positive responses were classified according to the New Vasovagal Syncope International Study (VASIS) classification 10 as an asystolic or VASIS 2B form (those with an asystole ≥3 s) or mixed or vasodepressor forms (all the other forms without asystole). TT was considered negative if syncope did not occur.
Study Protocol
After ILR implantation, all patients were followed up quarterly until the first documented syncopal recurrence, occurrence of a diagnostic arrhythmic event, or the end of the study. Events were classified according to the ISSUE classification 11 as: type 1 (asystole >3 s), type 2 (bradycardia), type 3 (slight or no rhythm variations), and type 4 (tachycardia).
For the purpose of this study, the selected group consisted of those patients who had performed a TT and had a diagnosis established by means of ILR documentation. Those with asystolic episodes received a dual-chamber pacemaker that was programmed in rate drop response pacing mode (lower rate of 40/min, drop size of 20 beats with a drop rate of 50/min within a detection window of 1 minute) and were followed up quarterly for 24 months or up to the first episode of recurrence of syncope. The control group consisted of those patients who, despite an established diagnosis, did not receive active treatment; there were 31 asystolic NMS patient (29 of whom assigned to inactive pacemaker arm of the randomized trial) and 14 not asystolic NMS.
The protocol was approved by a research ethics board at each center and each patient provided signed informed consent.
Statistical Analysis
Continuous data are shown as averages±SDs or medians (25th-75th percentile), as appropriate, whereas absolute and relative frequencies were used to describe categorical data. The Shapiro-Wilk test was performed to check the skewness of distributions. Continuous variables were compared by unpaired Student t test or a nonparametric Mann-Whitney test, depending on data distribution. Fisher exact test was used to compare proportions. Differences with a P value <0.05 were indicated. The time to the first recurrence of syncope was analyzed by means of Kaplan-Meier survival curves, which were compared using the log-rank test. Analyses were performed by means of SAS version 9.3 (Cary, NC).
Results
Study participants were enrolled from July 2006 to November 2010 and follow-up was concluded in November 2012. During the observation period, 162 of 504 patients had a presumed diagnosis of NMS documented by ILR, which showed an ECG pattern consistent with a reflex mechanism (ie, types 1, 2, and 3 of the ISSUE classification). 11 In another 25 patients, the ILR documented an event that was inconsistent with the diagnosis of NMS (eg, persistent atrioventricular block, brady-tachy syndrome, atrial or ventricular tachyarrhythmias); these patients were therefore excluded from the analysis.
Among the 162 patients with presumed NMS, TT was positive in 76 (during the passive phase in 22 and during drug challenge in 54) and negative in 60 (not performed in 26). Their clinical characteristics are listed in Table 1 . Patients with positive and negative TT had similar characteristics; apart from TT response, the 2 groups were indistinguishable. An asystolic response (type 2B of the VASIS classification) predicted a similar asystolic form during ILR monitoring (type 1 of the ISSUE classification), with a positive predictive value of 86% (95% confidence interval [CI], 70%-95%; Figure 1 ). The corresponding values were 48% in patients with non-asystolic TT (P=0.001 versus asystolic TT) and 58% in patients with negative TT (P=0.001 versus asystolic TT).
Fifty-two patients (26 TT+ and 26 TT-) with asystole documented by ILR received a pacemaker ( Figure 2 ). Apart from TT response, the 2 groups had similar clinical characteristics ( Table 2 ). Syncope recurred in 8 (31%) TT+ and in 1 (4%) TTpatients: it occurred in standing or sitting positions in all and was preceded by a prodrome in 8. At multivariable analysis, TT+ and total number of events were the only independent predictor of syncope recurrence ( Table I in the Data Supplement) . At the 21st month, the estimated product-limit syncope recurrence rates were 55% (95% CI, 29-85) and 5% (95% CI, 1-32), respectively (P=0.004). The recurrence rate in TT+ patients was similar to that seen in 45 untreated controls ( Table 2 ; Figure I in the Data Supplement), which was 64% (95% CI, 48-80; P=0.75). The 14 TT+ patients with an asystolic VASIS 2B response had a recurrence rate of 35% (95% CI, 13-75) at 12 months and of 57% (95% CI, 24-93) at 21 months; these rates were similar to those observed in 12 non-asystolic TT+ patients (P=0.53). There was a trend toward a longer median time to first syncope recurrence in the 4 asystolic TT+ patients who had syncopal recurrence than in the 4 non-asystolic TT+ patients who had syncopal recurrence: 8 (4-15) and 2 (0-4) months (P=0.1; Figure 3 ). Finally, 10 patients who had not performed TT had asystole documented by ILR and received a pacemaker: 1 had syncopal recurrence (estimated product-limit syncope recurrence rate at 21 months of 14% [95% CI, 2-67]).
Discussion
The study was able to provide some insight into pacing failure observed in a quarter of patients in the double-blind, randomized, ISSUE-3 trial. Indeed, we found that the benefit of pacemaker therapy in patients with presumed NMS and documented asystole was not substantial in those with a positive TT. Syncope recurrence was independent from the type of response during TT. Although an asystolic response during TT predicted spontaneous asystole, we were unable to show a benefit greater than in patients with non-asystolic responses. Therefore, we speculate that pacing failure was because of hypotensive syncope (either vasodepressor NMS or orthostatic hypotension), which is disclosed by TT susceptibility and which cannot be prevented by cardiac pacing. It is commonly accepted that hypotension plays a major role in all forms of TT-induced NMS and that it precedes (and perhaps triggers) bradycardia and syncope in the vast majority of patients even in those with cardioinhibitory syncope according to the modified VASIS classification. 12, 13 TT+ and TT-patients had similar clinical characteristics, similar outcomes, and similar ECG patterns when an episode was documented by ILR (Table 1 ). These findings had already emerged from the ISSUE 1 and ISSUE 2 studies 14, 15 and other studies in the literature. [16] [17] [18] [19] Although the 2 groups were indistinguishable in terms of clinical characteristics, the different effect of pacing prompts us to infer that the underlying mechanism of syncope is different, that is, that a vasodepressive mechanism is dominant in TT+ patients, whereas a cardioinhibitory mechanism is dominant in TT-patients. Thus, the use of TT shifts from that of a tool for clinical diagnosis to a tool for pathophysiological classification, with obvious therapeutic implications. Before the ISSUE-3 trial, cardiac pacing for NMS had only been evaluated in randomized trials which enrolled patients with TT+, 2-6 TT being considered the standard means of diagnosing NMS; no indication for pacing in TT-NMS patients existed. ISSUE-2 enrolled both TT+ and TT-patients but the outcome was not considered separately. 15 ISSUE-3 included both TT+ and TT-patients, and clinical history and initial evaluation were regarded as the standard for diagnosis. By showing that TT-NMS patients are those who benefit most from cardiac pacing, the present study inverts previous knowledge on indications for pacing.
In this subanalysis of ISSUE-3 study, pacemaker therapy in TT+ patients showed no benefit, despite the documentation of a long asystole at the time of a spontaneous event; the syncopal recurrence rate was also similar to the 37% and 57% rates observed at 1 and 2 years in the pacemaker-off arm of ISSUE-3. This result was largely unexpected as previous 5 major multicenter, randomized, controlled trials 2-6 performed on TT+ showed some efficacy of pacing even in the absence of documentation of spontaneous asystole. When pooled together, the 5 trials evaluated 318 patients; syncope recurred in 21% of the paced patients and in 44% of unpaced patients (P<0.001). A meta-analysis suggested a nonsignificant 17% reduction in syncope in the double-blind studies and a 84% reduction in the studies in which the control group did not receive a pacemaker. 20 Our study group was small and the confidence interval of the probability of recurrence of syncope at 21st month ranged from 29% to 85%. We cannot therefore exclude a type II error; some benefit of pacing may still be possible, especially in patients with an asystolic TT+ response. What we have observed here in NMS patients is similar to what was observed in patients paced for carotid sinus syndrome. In the study of Gaggioli et al, 21 patients with carotid sinus syndrome and TT+ had a 2.7-fold increased risk of syncopal recurrence compared with carotid sinus syndrome and TT-: at a mean follow-up of 33 months, syncope recurred in 21% of 70 patients versus 9% of 99 patients (P=0.02); positive TT was the only independent predictor of syncopal recurrence. Solari et al, 22 in 141 patients affected by carotid sinus syndrome, found that a mixed or vasodepressor response to TT was the only independent predictor of syncopal recurrence (hazards ratio, 1.8; P=0.01). In conclusion, in the light of the present study and of the above literature, it is clear that cardiac pacing is effective when TT is negative, whereas syncope can frequently recur when TT is positive.
Limitations
As discussed above, the study group was small with a large confidence interval of the probability of recurrence of syncope. Some benefit of pacing may still be possible in patients with positive TT response. For example, we observed a 4-fold longer median time to syncope recurrence (8 versus 2 months) in asystolic than in non-asystolic TT+ patients on pacemaker treatment. The same finding was observed in the SYNPACE (vasovagal SYNcope and PACing) trial, 6 in which the time to the first syncope recurrence was longer on pacemaker therapy than on placebo in patients who had shown an asystolic (ventricular pause of 13±8 s) response during tilt table testing: 97 versus 11 days (P=0.06). We did not evaluate the effect of cardiac pacing in asystolic TT+ patients who did not achieve the end point of an ILR event documentation; theoretically, these patients could have a better outcome with a pacemaker. It is not completely clear that all of patients had NMS. It is important to acknowledge that the ISSUE-3 population is by no means the typical NMS type of patients. Many ISSUE-3 patients were old and had atypical presentation with no or subtle prodrome and lack of recognizable triggers. NMS could not be confirmed by TT which was negative in half of the patients. It is possible that these patients simply had an intermittent form of extreme bradycardia (ie, asystole) different from NMS. A great overlap between extrinsic sinus node dysfunction and dysautonomic conditions exists. 23, 24 Idiopathic paroxysmal atrioventricular block has been described recently as a different cause of unexplained syncope in patients without structural heart disease. 25 Compared with TT-, TT+ patients treated with a pacemaker had a longer history of more syncopal episodes during life (but not in the past 2 years) and fewer were men. Albeit marginal, these differences could indicate a different susceptibility to NMS and partly influence pacing results.
Finally, this study suggests a strategy of pacing indication largely based on the result of TT, despite TT being regarded as having questionable diagnostic accuracy and reproducibility. 17, 19 For all the above reasons, the findings of the present results study cannot be taken as conclusive; the largely unexpected prompt future studies which may show similar results to ours.
Conclusions
In the present study, cardiac pacing was effective in NMS patients with documented asystolic episodes in whom TT was negative; conversely, there was insufficient evidence of efficacy from this data set in patients with a positive TT even when spontaneous asystole was documented. Present observations are unexpected and need to be confirmed by other studies. 
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